Ken Griffin Diagnostics & Research

Citadel Advisors LLC

$618 Billion
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
EXAS Exact Sciences Corp	$11.9B	$216 Million 0.03% of portfolio	3,941,587	Q3 2025 Added 805.07%
TMO Thermo Fisher Scientific Inc.	$222B	$170 Million 0.03% of portfolio	349,701	Q3 2025 Reduced 68.12%
NTRA Natera, Inc.	$19.8B	$144 Million 0.02% of portfolio	896,666	Q3 2025 Added 9.16%
MTD Mettler Toledo International Inc	$31.6B	$66.3 Million 0.01% of portfolio	53,972	Q3 2025 New
A Agilent Technologies, Inc.	$43.5B	$50.4 Million 0.01% of portfolio	392,663	Q3 2025 Reduced 76.17%
ICLR Icon PLC	$13.2B	$47.2 Million 0.01% of portfolio	269,979	Q3 2025 Reduced 86.13%
DHR Danaher Corp	$160B	$29.9 Million 0.0% of portfolio	150,800	Q3 2025 Added 73.43%
NEO Neogenomics Inc	$1.3B	$20.9 Million 0.0% of portfolio	2,710,791	Q3 2025 Added 364.3%
GH Guardant Health, Inc.	$9.65B	$19 Million 0.0% of portfolio	304,520	Q3 2025 Reduced 89.64%

CRL Charles River Laboratories International, Inc.	$8.54B	$18.5 Million 0.0% of portfolio	118,030	Q3 2025 Reduced 79.09%
DGX Quest Diagnostics Inc	$15.6B	$17.9 Million 0.0% of portfolio	130,614	Q3 2025 Added 364.9%
IDXX Idexx Laboratories Inc	$57.4B	$17.6 Million 0.0% of portfolio	27,576	Q3 2025 Reduced 36.43%
IQV Iqvia Holdings Inc.	$41B	$15 Million 0.0% of portfolio	78,888	Q3 2025 Added 1,109.01%
WAT Waters Corp	$22.7B	$14.9 Million 0.0% of portfolio	49,621	Q3 2025 Added 1,339.54%
MEDP Medpace Holdings, Inc.	$18.4B	$11.8 Million 0.0% of portfolio	22,913	Q3 2025 Reduced 66.79%
RDNT Rad Net, Inc.	$4.31B	$9.21 Million 0.0% of portfolio	120,873	Q3 2025 Added 107.54%
CDNA Care Dx, Inc.	$852M	$9.07 Million 0.0% of portfolio	623,813	Q3 2025 Reduced 21.1%
SHC Sotera Health CO	$4.42B	$8.73 Million 0.0% of portfolio	555,111	Q3 2025 Added 530.54%

FLGT Fulgent Genetics, Inc.	$881M	$8.4 Million 0.0% of portfolio	371,476	Q3 2025 Reduced 38.46%
CSTL Castle Biosciences Inc	$880M	$5.71 Million 0.0% of portfolio	250,915	Q3 2025 Reduced 71.76%
NEOG Neogen Corp	$1.38B	$4.94 Million 0.0% of portfolio	865,547	Q3 2025 Reduced 68.57%
MYGN Myriad Genetics Inc	$541M	$4.14 Million 0.0% of portfolio	572,150	Q3 2025 Reduced 66.56%
ILMN Illumina, Inc.	$19B	$4.07 Million 0.0% of portfolio	42,805	Q3 2025 Added 59.19%
PKI Perkinelmer Inc	$15.3B	$3.35 Million 0.0% of portfolio	27,652	Q3 2025 Added 114.66%
TWST Twist Bioscience Corp	$1.51B	$3.24 Million 0.0% of portfolio	115,245	Q3 2025 Reduced 92.34%
ACRS Aclaris Therapeutics, Inc.	$168M	$2.72 Million 0.0% of portfolio	1,432,677	Q3 2025 Added 25.26%
SERA Sera Prognostics, Inc.	$87.6M	$1.99 Million 0.0% of portfolio	653,746	Q3 2025 Added 3.93%
XGN Exagen Inc.	$147M	$1.27 Million 0.0% of portfolio	116,230	Q3 2025 New
LAB Standard Biotools Inc.	$97.5M	$634,000 0.0% of portfolio	488,443	Q3 2025 Added 39.89%
OPK Opko Health, Inc.	$988M	$433,000 0.0% of portfolio	279,875	Q3 2025 Added 28.74%
NOTV Inotiv, Inc.	$25.9M	$358,000 0.0% of portfolio	255,858	Q3 2025 Added 95.52%
VNRX Volitionrx LTD	$18.9M	$224,000 0.0% of portfolio	329,520	Q3 2025 Added 70.08%

Shares Options

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track Ken Griffin's portfolio

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account